Association of tumor immune microenvironment profiling and 21-gene recurrence assay in early breast cancer patients

被引:3
|
作者
Tong, Yiwei [1 ]
Huang, Jiahui [1 ]
Ren, Weili [2 ]
Yu, Jing [1 ]
Zhang, Xu [1 ]
Wang, Zheng [1 ]
Hong, Jin [1 ]
Gao, Weiqi [1 ]
Wu, Jiayi [1 ]
Ji, Min [3 ]
Shen, Kunwei [1 ]
Chen, Xiaosong [1 ]
机构
[1] Shanghai Jiao Tong Univ, Ruijin Hosp, Comprehens Breast Hlth Ctr, Dept Gen Surg,Sch Med, 197 Ruijin Er Rd, Shanghai 200025, Peoples R China
[2] Shaoxing Shangyu Peoples Hosp, Dept Breast Surg, Shaoxing 312300, Zhejiang, Peoples R China
[3] Shanghai Jiao Tong Univ, Int Peace Matern & Child Hlth Hosp, Dept Breast, Sch Med, 910 Hengshan Rd, Shanghai 200030, Peoples R China
基金
中国国家自然科学基金;
关键词
Breast cancer; Tumor immune microenvironment; Immune profiling; 21-gene recurrence score; Prognosis; INTERNATIONAL EXPERT CONSENSUS; INFILTRATING LYMPHOCYTES; PRIMARY THERAPY; DUCTAL CARCINOMA; PROGNOSTIC VALUE; HIGHLIGHTS; ADJUVANT; PROPOSAL; TRIALS;
D O I
10.1186/s40001-022-00917-3
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Introduction: Tumor immune microenvironment (TIME) plays a vital role in breast cancer development, treatment resistance, and prognosis. This study evaluates the association of TIME profiling and 21-gene recurrence score (RS) in early Luminal breast cancer patients.Methods: ER+ /HER2-, pN0 breast cancer patients with available RS results who received surgery between January 2009 and December 2013 were enrolled. TIME markers, including stromal tumor infiltrating lymphocytes (TILs), CD3, CD4, CD8, and tumor PD-L1 expression, were comprehensively analyzed. Association of TIME markers with RS, as well as their correlation with breast cancer-specific survival (BCSS) were tested.Results: Overall, 385 patients were included, of whom 341 (88.6%) had TILs <= 10%. TIME markers were positively but moderately correlated with each other (Spearman r 0.28-0.53, all P < 0.05). Continuous RS showed a weak correlation with continuous TILs, CD3, CD8, and PD-L1. Regarding single gene mRNA level in the 21-gene RS panel, higher expression of TIME markers was related to lower ER group genes expression, but higher proliferation and invasion group genes level. After a median follow-up of 91.67 (range 5.03-134.03) months, TILs (P = 0.049) and PD-L1 (P = 0.034) were inversely associated with BCSS.Conclusions: Breast cancer TIME markers, including TILs, CD3, CD4, CD8, and PD-L1, were correlated with 21-gene RS score. Lower expression of ER group genes, as well as higher expression of proliferation and invasion group genes were associated with a higher level of these TIME markers, warranting further exploration.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Patterns of 21-Gene Assay Testing and Chemotherapy Use in Black and White Breast Cancer Patients
    Sheppard, Vanessa B.
    O'Neill, Suzanne C.
    Dilawari, Asma
    Horton, Sara
    Hirpa, Fikru A.
    Isaacs, Claudine
    CLINICAL BREAST CANCER, 2015, 15 (02) : E83 - E92
  • [42] Effect of 21-gene recurrence score in decision-making for surgery in early stage breast cancer
    Wu, San-Gang
    Zhang, Wen-Wen
    Wang, Jun
    Dong, Yong
    Chen, Yong-Xiong
    He, Zhen-Yu
    ONCOTARGETS AND THERAPY, 2019, 12 : 2071 - 2078
  • [43] Distribution of 21-Gene Recurrence Scores Among Breast Cancer Histologic Subtypes
    Kizy, Scott
    Huang, Jing Li
    Marmor, Schelomo
    Blaes, Anne
    Yuan, Jianling
    Beckwith, Heather
    Tuttle, Todd M.
    Hui, Jane Yuet Ching
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2018, 142 (06) : 735 - 741
  • [44] Primary 21-Gene Recurrence Score and Disease Outcome in Loco-Regional and Distant Recurrent Breast Cancer Patients
    Lu, Yujie
    Tong, Yiwei
    Huang, Jiahui
    Lin, Lin
    Wu, Jiayi
    Fei, Xiaochun
    Huang, Ou
    He, Jianrong
    Zhu, Li
    Chen, Weiguo
    Li, Yafen
    Chen, Xiaosong
    Shen, Kunwei
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [45] Clinical analysis of 21-gene recurrence score test in hormone receptor-positive early-stage breast cancer
    Zhu, Lizhe
    Ma, Nan
    Wang, Bin
    Zhou, Can
    Yan, Yu
    Wang, Ke
    He, Jianjun
    Ren, Yu
    ONCOLOGY LETTERS, 2019, 17 (06) : 5469 - 5480
  • [46] Cost-Effectiveness of the 21-Gene Assay for Guiding Adjuvant Chemotherapy Decisions in Early Breast Cancer
    Paulden, Mike
    Franek, Jacob
    Pham, Ba'
    Bedard, Philippe L.
    Trudeau, Maureen
    Krahn, Murray
    VALUE IN HEALTH, 2013, 16 (05) : 729 - 739
  • [47] 21-Gene Recurrence Score Assay and Outcomes of Adjuvant Radiotherapy in Elderly Women With Early-Stage Breast Cancer After Breast-Conserving Surgery
    Wu, San-Gang
    Zhang, Wen-Wen
    Wang, Jun
    Dong, Yong
    Sun, Jia-Yuan
    Chen, Yong-Xiong
    He, Zhen-Yu
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [48] Cost-utility analysis of 21-gene assay for node-positive early breast cancer
    Masucci, L.
    Torres, S.
    Eisen, A.
    Trudeau, M.
    Tyono, I
    Saunders, H.
    Chan, K. W.
    Isaranuwatchai, W.
    CURRENT ONCOLOGY, 2019, 26 (05) : 307 - 318
  • [49] The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use
    Eiermann, W.
    Rezai, M.
    Kuemmel, S.
    Kuehn, T.
    Warm, M.
    Friedrichs, K.
    Schneeweiss, A.
    Markmann, S.
    Eggemann, H.
    Hilfrich, J.
    Jackisch, C.
    Witzel, I.
    Eidtmann, H.
    Bachinger, A.
    Hell, S.
    Blohmer, J.
    ANNALS OF ONCOLOGY, 2013, 24 (03) : 618 - 624
  • [50] Prognostic value of the 21-gene recurrence score for regional recurrence in patients with estrogen receptor-positive breast cancer
    Minji Koh
    Jinhong Jung
    Su Ssan Kim
    Seung Do Ahn
    Eun Kyung Choi
    Il Yong Chung
    Jong Won Lee
    Sung-Bae Kim
    Jae Ho Jeong
    Breast Cancer Research and Treatment, 2021, 188 : 583 - 592